FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898083043> ?p ?o ?g. }

• W2898083043 abstract "Introduction The study objective is to assess the safety and performance of Neuroform Atlas Stent in the treatment of intracranial aneurysms. The protocol allowed for use of all types of coils and adjunctive technologies as deemed appropriate by the participating investigators. The primary study endpoint is the permanent morbidity and mortality rate, defined as any major ipsilateral stroke or neurological death within 12 to 16 months following the procedure. The study is still ongoing. We present here a descriptive analysis of procedure feasibility, clinical safety and acute angiographic results. Methods A total of 104 patients were included. Most patients were female (76%) with a mean age 55.1 year (SD=10.1). Sixteen patients (15%) had a prior (non-target) aneurysm treated. Most target aneurysms (n=82) were unruptured and elective cases (79.6%); 7 (6.8%) were symptomatic, and 9 (8.7%) were previously ruptured. Sixteen (15.5%) of target aneurysms had been previously treated. The size of aneurysms was 12 mm: 3 (2.9%). At baseline, 91 patients (87.5%) were symptom free (mRS=0), 11 mRS=1 and 2 mRS=2. Antiplatelet drugs were administrated prior, during and after the procedure according to each institution’s protocol and under the supervision of each participating investigator. Results A total of 129 Neuroform Atlas Stents were used in 104 patients (i.e. 2 stents in 20 patients, 3 and 4 stents each in one patient). In one patient, the stenting initially planned was abandoned. Major reason for using more than 2 stents was Y-stenting for bifurcation aneurysm. The stent was successfully implanted in 94.5% (121/128) of cases. The preferred coil delivery technique used was jailing (62.5%, n=65). Six procedural complications were observed including 2 in-stent thrombosis, 1 arterial occlusion, 1 access site complication, 1 contrast media encephalopathy and 1 perforation of the parent vessel. The latter event led to the patient death two days after the procedure. Upon the procedure, a complete aneurysm occlusion was observed in 69 patients (66.3%), residual neck and residual aneurysm were reported respectively in 22 (21.2%) and 13 (12.5%) patients. Mean time to discharge from hospital after the procedure was 3.29 days; none had undergone a re-intervention of target aneurysm at discharge. Eighteen patients (17.3%) experienced at least one adverse event between the procedure and discharge; 5 were serious, 12 of 22 events were not related to stent nor to the procedure. Acute clinical and angiographic assessments were self-reported. Conclusion These interim results suggest that Neuroform Atlas Stent System is a safe device and permit adequate aneurysm embolization; Final study analysis will allow for assessing system effectiveness and long-term safety. Disclosures A. Bonafe: 2; C; Stryker, Medtronic, MicroVention, Phenox, Balt. V. Costalat: 1; C; Stryker. 2; C; Medtronic, Balt, MicroVention, Stryker, Phenox. P. Schramm: 1; C; Siemens Healthineers, Penumbra. 2; C; Stryker, Penumbra. 3; C; Phenox, Cerenovus, Bracco, Bayer, Penumbra, Stryker, Siemens Healthineers. T. Eckey: 2; C; Stryker, Penumbra. X. Barreau: None. G. Marnat: None. M. Piotin: 2; C; Stryker, Medtronic, MicroVention, Balt, Penumbra. A. Berlis: 2; C; Stryker. W. Weber: 2; C; Medtronic, MicroVention, Xenon. 3; C; Penumbra, Stryker. K. Zelenak: None. A. Narata: None. M. Hartmann: 2; C; Stryker. J. Gentric: 2; C; Stryker. E. Houdart: 6; C; Stryker." @default.
• W2898083043 created "2018-10-26" @default.
• W2898083043 creator A5003026098 @default.
• W2898083043 creator A5004303005 @default.
• W2898083043 creator A5017098837 @default.
• W2898083043 creator A5020121176 @default.
• W2898083043 creator A5026579594 @default.
• W2898083043 creator A5033205457 @default.
• W2898083043 creator A5039914669 @default.
• W2898083043 creator A5058666169 @default.
• W2898083043 creator A5060153262 @default.
• W2898083043 creator A5066520460 @default.
• W2898083043 creator A5069551770 @default.
• W2898083043 creator A5075356103 @default.
• W2898083043 creator A5075674410 @default.
• W2898083043 creator A5087503172 @default.
• W2898083043 date "2018-07-01" @default.
• W2898083043 modified "2023-09-27" @default.
• W2898083043 title "E-040 Safety and performance of the neuroform atlasTM stent system in the treatment of intracranial aneurysms: a prospective, observational, multicentre, post-market european study (atlas EU PMCF study)" @default.
• W2898083043 doi "https://doi.org/10.1136/neurintsurg-2018-snis.116" @default.
• W2898083043 hasPublicationYear "2018" @default.
• W2898083043 type Work @default.
• W2898083043 sameAs 2898083043 @default.
• W2898083043 citedByCount "0" @default.
• W2898083043 crossrefType "proceedings-article" @default.
• W2898083043 hasAuthorship W2898083043A5003026098 @default.
• W2898083043 hasAuthorship W2898083043A5004303005 @default.
• W2898083043 hasAuthorship W2898083043A5017098837 @default.
• W2898083043 hasAuthorship W2898083043A5020121176 @default.
• W2898083043 hasAuthorship W2898083043A5026579594 @default.
• W2898083043 hasAuthorship W2898083043A5033205457 @default.
• W2898083043 hasAuthorship W2898083043A5039914669 @default.
• W2898083043 hasAuthorship W2898083043A5058666169 @default.
• W2898083043 hasAuthorship W2898083043A5060153262 @default.
• W2898083043 hasAuthorship W2898083043A5066520460 @default.
• W2898083043 hasAuthorship W2898083043A5069551770 @default.
• W2898083043 hasAuthorship W2898083043A5075356103 @default.
• W2898083043 hasAuthorship W2898083043A5075674410 @default.
• W2898083043 hasAuthorship W2898083043A5087503172 @default.
• W2898083043 hasConcept C126322002 @default.
• W2898083043 hasConcept C126838900 @default.
• W2898083043 hasConcept C127413603 @default.
• W2898083043 hasConcept C141071460 @default.
• W2898083043 hasConcept C168563851 @default.
• W2898083043 hasConcept C203092338 @default.
• W2898083043 hasConcept C23131810 @default.
• W2898083043 hasConcept C2776098176 @default.
• W2898083043 hasConcept C2778583881 @default.
• W2898083043 hasConcept C2780645631 @default.
• W2898083043 hasConcept C71924100 @default.
• W2898083043 hasConcept C78519656 @default.
• W2898083043 hasConceptScore W2898083043C126322002 @default.
• W2898083043 hasConceptScore W2898083043C126838900 @default.
• W2898083043 hasConceptScore W2898083043C127413603 @default.
• W2898083043 hasConceptScore W2898083043C141071460 @default.
• W2898083043 hasConceptScore W2898083043C168563851 @default.
• W2898083043 hasConceptScore W2898083043C203092338 @default.
• W2898083043 hasConceptScore W2898083043C23131810 @default.
• W2898083043 hasConceptScore W2898083043C2776098176 @default.
• W2898083043 hasConceptScore W2898083043C2778583881 @default.
• W2898083043 hasConceptScore W2898083043C2780645631 @default.
• W2898083043 hasConceptScore W2898083043C71924100 @default.
• W2898083043 hasConceptScore W2898083043C78519656 @default.
• W2898083043 hasLocation W28980830431 @default.
• W2898083043 hasOpenAccess W2898083043 @default.
• W2898083043 hasPrimaryLocation W28980830431 @default.
• W2898083043 hasRelatedWork W1988167208 @default.
• W2898083043 hasRelatedWork W2057936029 @default.
• W2898083043 hasRelatedWork W2091973686 @default.
• W2898083043 hasRelatedWork W2095247648 @default.
• W2898083043 hasRelatedWork W2111268578 @default.
• W2898083043 hasRelatedWork W2167814197 @default.
• W2898083043 hasRelatedWork W2360745124 @default.
• W2898083043 hasRelatedWork W2386769168 @default.
• W2898083043 hasRelatedWork W2397884650 @default.
• W2898083043 hasRelatedWork W256020048 @default.
• W2898083043 isParatext "false" @default.
• W2898083043 isRetracted "false" @default.
• W2898083043 magId "2898083043" @default.
• W2898083043 workType "article" @default.